Frontlight ResearchEarly access
CompletedNo phase
Diagnostic and Prognostic Roles of Procalcitonin and Highly Sensitive C-Reactive Protein in Early Detection of Burn Sepsis
Key facts
- Who runs it
- Mansoura University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 1 Sept 2025
- Ended
- 1 Jul 2026
- Type of study
- Observational
- Treatments tested
- Measurement of Procalcitonin level
- Measurement of c-reactive protein level
- Record updated
- 27 August 2026
Who can take part
- Age
- 3 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Age from 3 years to 65 years
- Both sexes
- Patients with major burn (2nd and 3rd degrees of burn)
Who cannot take part
- Patients with uncompensated chronic disease e.g. hepatic, renal
- Patients with unrealistic expectations
- Patients with inhalational burn injury
- Patients with mental or psychological troubles affecting the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aimed to evaluate the value of procalcitonin and highly sensitive c-reactive protein as biomarkers for early detection of sepsis in patients with major burns.
The group in the trial
- Study group
Patients with major burn (2nd and 3rd degrees of burn)
Treatment: Measurement of Procalcitonin level and Measurement of c-reactive protein level
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 27 August 2026